Owlet Inc Stock Price, News & Analysis

Owlet (NYSE: OWLT) selected OpenSynergy's Blue SDK to provide Bluetooth® connectivity for its new Dream Sight camera baby monitor, aiming to improve connection stability, interoperability, and security across iOS and Android devices.

The Blue SDK is pre-qualified with the Bluetooth SIG, which Owlet says streamlined qualification and certification. Owlet highlighted faster development timelines, ongoing security monitoring by OpenSynergy, and broader Bluetooth feature support; Dream Sight is available now alongside Dream Sock and Dream Duo, and Owlet reports being trusted by over 2.5 million families in 30+ countries.

Owlet (NYSE: OWLT) announced a partnership with Locus Health on November 19, 2025 to integrate data from Owlet’s FDA-cleared BabySat prescription device into Locus Health’s remote patient monitoring platform. The integration delivers ongoing, secure access to infant vitals — including oxygen saturation and pulse rate — into clinicians’ existing workflows after hospital discharge.

This collaboration aims to improve continuity of care for infants leaving ICU, reduce manual data entry and transcription errors, and extend monitoring for complex conditions while leveraging Owlet’s scale (over 2.5 million babies monitored).

Owlet (NYSE:OWLT) reported record Q3 2025 results: revenue $32.0M (+44.6% YoY), gross profit $16.2M (gross margin 50.6%), operating income $1.2M and net income $4.1M$1.6M. Management cited tariff impacts that reduced gross margin by 150 basis points and noted strong international growth (~171% YoY) with an India regulatory clearance expected for early 2026. Owlet360 subscriptions surpassed 85,000 paying subscribers. Updated 2025 guidance: revenue $103M–$106M, gross margin 48%–50% (including tariffs), and adjusted EBITDA $1.25M–$2.0M. A warrant exchange and follow-on equity offering completed in October.

Owlet (NYSE: OWLT) announced a partnership with Rhapsody on November 12, 2025 to connect infant monitoring data from Owlet’s FDA-cleared prescription pulse oximeter, BabySat, into electronic health record (EHR) workflows.

The integration uses standards-based connectivity to send clinically validated infant vital signs into provider EHRs, aiming to reduce custom development, minimize errors, and allow clinicians to view continuous, real-time home-monitoring data within existing patient records. The partnership is positioned to support scaling pediatric remote patient monitoring programs and strengthen home-to-hospital data sharing.

Owlet (NYSE: OWLT) announced that its Dream Sight baby monitor is the first and only monitor to earn the SGS Cybersecurity Mark, after testing by Brightsight and EU Type Certification by SGS Fimko Oy under the European Radio Equipment Directive (RED) Articles 3(3)(d) and (e).

Launched in September 2025, Dream Sight features 2K HD streaming, night vision, motion/sound detection, two-way audio, and temperature/humidity tracking, and can integrate with the FDA-cleared Dream Sock for clinically validated vital signs and wellness trends.

Owlet (NYSE: OWLT) will report third quarter 2025 financial results after market close on Thursday, November 13, 2025. The company said President & CEO Jonathan Harris and CFO Amanda Twede Crawford will host a conference call at 4:30 p.m. ET the same day to discuss results and provide a business update.

Participants can join by phone at 833-470-1428 (domestic) or 646-844-6383 (international) using Access Code 428622. A simultaneous webcast and replay will be available in the Events section of Owlet's Investor Relations website at investors.owletcare.com.

Owlet (NYSE: OWLT) priced an underwritten public offering of 4,196,000 shares of Class A common stock at $7.15 per share, with gross proceeds expected to be approximately $30.0 million.

The company granted underwriters a 30‑day option to purchase up to an additional 629,400 shares at the public offering price less underwriting discounts and commissions. The offering is expected to close on or about October 23, 2025, subject to customary closing conditions.

Owlet intends to use net proceeds to support continued commercialization, research and development, and general corporate purposes. William Blair and TD Cowen are joint bookrunners; Craig‑Hallum is co‑manager. The offering is made pursuant to an effective Form S‑3 registration statement.

Owlet (NYSE: OWLT) announced a proposed underwritten public offering of its Class A common stock on October 21, 2025. The company said it will grant underwriters a 30-day option to buy up to 15% additional shares at the offering price less underwriting discounts and commissions. All shares are being offered by Owlet, with net proceeds intended to support continued commercialization, research and development, and general corporate purposes.

William Blair and TD Cowen are joint bookrunners and Craig-Hallum is co-manager. The offering is subject to market conditions and will be made by prospectus supplement filed under Owlet’s effective Form S-3 (File No. 333-281556). Prospective investors can obtain the preliminary prospectus supplement from the underwriters or the SEC website.

Owlet (NYSE: OWLT) received CDSCO approval to distribute Dream Sock in India and plans a broader launch of Dream Sock, Dream Sight and Dream Duo in early 2026. The company says its wearable Dream Sock monitors oxygen and pulse for infants 0–18 months (2.5–13.6 kg) and pairs with the Dream App and Base Station for real-time alerts. Owlet noted India’s large birth cohort (~23 million babies expected in 2025), >80% urban smartphone penetration, and that its products are already used by 2 million families in 30+ countries.